Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect

Clinical Chemistry

Volumn 45, Issue 9, 1999, Pages 1477-1484

  Stein, C Michael ^a   Murray, John J ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; PHYTOHEMAGGLUTININ P;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION;

STAPHYLOCOCCUS PHAGE 187;

EID: 0032846279     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.9.1477     Document Type: Article

References (32)

1. Burke JFJ, Pirsch JD, Ramos EL, Saloman DR, Stablein DM, Van Buren DH, West JC. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994;331:358-63.
2. Anonymous. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986;314: 1219-25.
3. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993:24:472-95.
4. Sketris I, Yatscoff R, Keown P, Canafax DM, First MR, Holt DW, et al. Optimizing the use of cyclosporine in renal transplantation. Clin Biochem 1995;28:195-211.
5. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996;30:107-40.
6. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995;17:631-7.
7. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995:17:642-54.
8. Wahlberg J, Wilczek HE, Fauchald P, Nordal KP, Heaf JG, Olgaard K, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995;60:648-52.
9. Kovarik JM, Mueller EA, van Bree JB, Fluciger SS, Lange H, Schmidt B, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 1994;58:658-63.
10. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter-and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83: 444-6.
11. Friman S, Backman L. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet 1996;30:181-93.
12. Kerman RH, Kimball PM, Lindholm A, Van Buren CT, Katz SM, Lewis RM, et al. Immune risk factors: impact on the incidence and diagnosis of rejection. Transplant Proc 1993;25:23-5.
13. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-5.
14. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992;23:428-48.
15. Hirano T, Oka K, Takeuchi H, Kazaki K, Matsuno N, Nagao T, et al. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis and psoriasis: possible implications for individual therapeutic efficacy. Clin Pharmacol Ther 1997;62:652-64.
16. Simpson MA, Young-Fadok TM, Madras PN, Freeman RB, Dempsey RA, Shaffer D, et al. Sequential interleukin 2 and interleukin 2 receptor levels distinguish rejection from cyclosporine toxicity in liver allograft recipients. Arch Surg 1991;126:717-9.
17. d'Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich S J, Gupta SK, Lantz MV, et al. Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol 1995;35:967-73.
18. Yoshimura N, Kahan BD. Pharmacodynamic assessment of the in vive cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients. Transplantation 1985;40: 661-6.
19. Hirano T, Oka K, Umezawa Y, Hirata M, Oh, Koga M. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis. Clin Pharmacol Ther 1998;63:465-70.
20. Lensmeyer GL, Wiebe DA, Carlson IH. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clin Chem 1989;35:56-63.
21. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vive is rapidly reversible. J Clin Investig 1995;96:1254-60.
22. Murray J J, Mullins MD, Knapp HR, Keeler SL, Serafin WE, Roberts LI, et al. Regulation of the immune response by eicosanoids: pharmacology and clinical effects of prostaglandin E in aspirinsensitive syndromes. Am J Ther 1995;2:739-48.
23. De Groote D, Gevaert Y, Lopez M, Gathy R, Fauchet F, Dehart I, et al. Novel method for the measurement of cytokine production by a one-stage procedure. J Immunol Methods 1993;163:259-67.
24. Zangerle PF, De Groote D, Lopez M, Meulman R J, Vrindis Y, Fauchet F, et at. Direct stimulation of cytokines (IL-1 β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. II. Application to rheumatoid arthritis and osteoarthritis. Cytokine 1992;4:568-75.
25. Elsasser-Beile U, von Kleist S, Gallati H. Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Methods 1991;139:191-5.
26. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK.506-, CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992;357:692-4.
27. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
28. Guillou PJ, Giles GR, Ramsden CW. Natural killer-cell activity, interferon-α2 production, and interleukin-2 production in cyclosporine-treated and conventionally immunosuppressed human allograft recipients. J Clin Immunol 1986;6:373-80.
29. McKenna RM, Rush DN, Bakkestad-Legare P, Jeffery JR, Interleukin 2, interferon, lymphotoxin in renal transplant recipients. Transplantation 1988;45:76-81.
30. Tkaczuk J, Rostaing L, Puyoo O, Peres C, Abbal M, Durand D, Ohayon E. Flow cytometry detection of intracytoplasmic cytokines after Neoral or sirolimus intake is an informative tool for monitoring in vivo immunosuppressive efficacy in renal transplant recipients. Transplant Proc 1998;30:2400-1.
31. van den Berg AP, Twilhaar WN, Mesander G, van Son WJ, van der Bij W, Klompmaker IJ, et al. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998;65:1066-71.
32. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUG monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.